Tony Chan has more than 15 years of experience advising companies on mergers and acquisitions (M&A), private equity, growth equity, and venture capital transactions, as well as on corporate governance, emerging company representation, and corporate finance. Tony’s clients include strategic buyers and sellers as well as financial sponsors and their portfolio companies in the life sciences, investment management, technology, and video game sectors. He also regularly advises on complex international and cross-border matters.
Tony serves as an adjunct professor at Georgetown Law School where he teaches Takeovers, Mergers and Acquisitions. He is also active in the community, serving on the steering committee for the Corporate and Securities community of the DC Bar and on the boards of the Arlington Arts Center and the Harvard Law School Association of DC.
Tony also maintains an active pro bono practice, serving as counsel to a number of nonprofit organizations, including Aequitas, APAI Vote, Rebuilding Together Philadelphia, the Philadelphia Film Society, and the Pennsylvania Coalition Against Rape, in addition to a number of charter schools, including Rocketship Education and North Star.
Tony has been recognized for his life sciences and M&A work by a number of notable publications, including The Legal 500 US, Law360, IFLR1000, and Legal Media Group. In particular, Law360 highlighted his work in navigating the complex life sciences industry and key partnership negotiations between biotechnology and drug companies.
Represented Celgene Corporation on numerous transactions, including its acquisition of Avila Therapeutics for up to US$925 million and its collaborations and equity investments with Jounce Therapeutics, Inc.; Juno Therapeutics, Inc.; Nurix, Inc.; Sutro BioPharma; Forma Therapeutics Holdings; Oncomed; and Epizyme.
Represented Ipsen S.A. in connection with its acquisition of global oncology assets from Merrimack Pharmaceuticals for up to US$1 billion.
Represented Ferring Pharmaceuticals on its acquisitions of: acquisition of Cytokine PharmaSciences Inc. and Controlled Therapeutics (Scotland) Ltd.; Lysteda from Xanodyne Pharmaceuticals, Inc.; DDAVP from Sanofi; Milprosa from Teva Women’s Health, Inc.; and orthobiologic product candidates from BioSurface Engineering Technologies Inc.
Represented R-Pharm US in its acquisition of Ixempra from Bristol-Myers Squibb.
Represented Mirae Asset Global Investments Co., Ltd. in its acquisition of Global X Management Company LLC, a New York-based provider of ETFs.
Represented Guggenheim Investments in its acquisition of Accretive Asset Management LLC.
Represented Ameriprise Financial in its sale of retail custodial and transfer agency businesses and acquisition of Emerging Global Advisers.
Represented Marble Point Credit Management in its acquisition of American Capital CLO Management.
Represented Pretium Capital Management in its acquisition of Valcour Capital Management.
Represented William Blair & Company in its acquisition of hedge-fund-of-funds firm Guidance Capital.
Represented Stripes Group, a leading growth equity firm, in its investments, including Art.com, Audionetwork, BlackTux, Blue Apron, BookMyShow, Califia Farms, Craftsy, eMarketer, Flatiron Health, Gimlet Media, GoFundMe, GrubHub, Kareo, Ketra Lighting, MyWebGrocer, Netbiscuits, On Running, Pond5, Refinery29, Reformation, Remitly, Sandata, Sift Sceinces, SPINS, Stella & Chewy’s, Voyetra Turtle Beach, Udemy, and Upwork.
Represented Turtle Beach Corporation in its acquisition of Parametric Sound Corporation.
Represented companies in the video game space in a wide variety of matters, including licensing, distribution, development, supply, manufacturing, co-promotion, sponsorship, e-sports and influencer agreements as well as with respect to IP, data protection and regulatory compliance.
Represented growth equity funds in their investments in Fortnite publisher Epic Games and various Chinese e-commerce companies, including Meituan and Miss Fresh.
Represented the special committee of the board of directors of XO Holdings, Inc. in connection with the acquisition of XO Holdings by Icahn affiliate, ACF Industries Holding Corp.
*Matters were handled prior to joining Morgan Lewis.
Harvard Law School, 2003, J.D.
Tulane University, 2000, B.A., magna cum laude
District of Columbia
Awards and Affiliations
Rising Star, IFLR1000 United States (2018)
Rising Star, IFLR1000 Financial and Corporate (2017, 2019)
Next Generation Lawyer, Life Sciences, The Legal 500 US (2017)
Rising Star, Life Sciences, Law360 (2016)
Rising Star, Corporate/M&A, Legal Media Group (2015, 2016)